Biotechnology
Auxilium Biotechnologies Launches Clinical Trial For Nerve Regeneration Medical Device
.png?ext=.png "Business Wire"){kind=small}
Share
Innovative research study aims to restore function and improve quality of life for patients with nerve injuries, leveraging cutting-edge regenerative science
SAN DIEGO--(BUSINESS WIRE)--#Auxilium--Auxilium Biotechnologies, a leader in regenerative medicine, is pleased to announce the enrollment of the first patient in its clinical trial evaluating the safety and efficacy of NeuroSpan BridgeTM, an innovative investigational device designed to improve nerve regeneration.
The pivotal trial, named Neurospan-1, is a study that aims to enroll 80 patients across the United States. The study will assess the device’s performance, safety profile, and potential benefits over existing treatment options. NeuroSpan Bridge is designed to accelerate nerve regeneration and nerve targeting, restoring motor and sensory function while reducing complications and side effects such as chronic pain observed in current treatments.
This trial represents a significant step forward in the company’s mission to restore lost function for individuals suffering from debilitating nerve injuries to the extremities, including those resulting from trauma such as car accidents or work-related injuries.
"We’ve spent years developing a technology with the potential to change lives, and today, we are one step closer to making that a reality," said Jacob Koffler, PhD, MBA, CEO of Auxilium.
This technology combines Auxilium Biotechnologies’ expertise in regenerative science, biomaterials, and medical device manufacturing. The initiation of this study reinforces its commitment to improving patient care through scientific excellence and innovation.
Auxilium’s commitment to scientific innovation extends beyond traditional boundaries, as demonstrated by its pioneering work in microgravity bioprinting, which successfully produced implantable medical devices aboard the International Space Station.
For more information about the clinical trial, please visit https://auxiliumbio.com/
About Auxilium Biotechnologies
Auxilium Biotechnologies is a pioneering biotechnology company dedicated to developing innovative solutions to treat traumatic injuries to the nervous system. With a focus on innovation and collaboration, the company develops cutting-edge bioprinting solutions and implantable medical devices to improve lives worldwide.
Contacts
Media Contact:
Daniel Delson
daniel@magnitude-growth.com
917.328.9337
Frequently Asked Questions
What is NeuroSpan Bridge?
NeuroSpan Bridge is an innovative investigational device designed to improve nerve regeneration and nerve targeting, restoring motor and sensory function.
What is the Neurospan-1 trial?
The Neurospan-1 trial is a pivotal study that aims to enroll 80 patients across the United States to assess the NeuroSpan Bridge device’s performance, safety profile, and potential benefits.
What is Auxilium Biotechnologies' mission?
Auxilium Biotechnologies is dedicated to developing innovative solutions to treat traumatic injuries to the nervous system and improve lives worldwide through scientific excellence and innovation.
First published on Fri, May 23, 2025
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Loading comments...